Strand Therapeutics announced on Thursday that it landed a $153 million Series B funding led by Kinnevik. The company’s ...

Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, secures a spot on Fortune's 2025 list of the 100 Most ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

NEW YORK, NY-Reshma Kewalramani, the Mumbai-born CEO of Vertex Pharmaceuticals, has been named one of the 100 Most Powerful ...

Mars partners with biotech firm Pairwise to develop climate-resilient cacao using CRISPR technology, aiming to safeguard the ...

Following these transactions, Kewalramani directly owns 115,968 shares of Vertex Pharmaceuticals. Based on InvestingPro analysis, the stock currently trades below its Fair Value, with analysts setting ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The postoperative pain management market is witnessing steady growth, driven by the rising number of surgical procedures globally and increasing awareness of effective pain control. Advancements in ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Lilly paid $47.5 million upfront to license the non-opioid pain drug candidate CNTX-0290 from Centrexion in 2019. The SSTR4 ...

It’s a fair question — and one genuinely difficult to answer about a president who thrives on outrage and leans heavily into ...

Metro Bank Holdings PLC (NYSE: MCB) (LSE:MTRO) results are flagged by market analyst Victoria Scholar at Interactive Investor ...